摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(3-((5-chloro-2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acetonitrile

中文名称
——
中文别名
——
英文名称
2-(3-((5-chloro-2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acetonitrile
英文别名
2-[3-[[5-Chloro-2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]acetonitrile;2-[3-[[5-chloro-2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]acetonitrile
2-(3-((5-chloro-2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acetonitrile化学式
CAS
——
化学式
C23H23ClFN7
mdl
——
分子量
451.934
InChiKey
ATZJUJWJYQTMGP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    32
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.26
  • 拓扑面积:
    80.1
  • 氢给体数:
    2
  • 氢受体数:
    8

反应信息

点击查看最新优质反应信息

文献信息

  • JAK2 and ALK2 inhibitors and methods for their use
    申请人:Tolero Pharmaceuticals, Inc.
    公开号:US10202356B2
    公开(公告)日:2019-02-12
    Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    本发明公开了具有 ALK2 激酶和/或 JAK2 激酶抑制剂活性的化合物。这些化合物具有以下结构 (I): 其中 R1、R2、R3、R4、R5、R6、R7、R8、X、z 和 A 如本文所定义。此外,还公开了与制备和使用此类化合物相关的方法,以及包含此类化合物的药物组合物。
  • JAK1 and ALK2 inhibitors and methods for their use
    申请人:Tolero Pharmaceuticals, Inc.
    公开号:US10752594B2
    公开(公告)日:2020-08-25
    Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    本发明公开了具有 ALK2 激酶和/或 JAK2 激酶抑制剂活性的化合物。这些化合物具有以下结构 (I): 其中 R1、R2、R3、R4、R5、R6、R7、R8、X、z 和 A 如本文所定义。此外,还公开了与制备和使用此类化合物相关的方法,以及包含此类化合物的药物组合物。
  • JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE
    申请人:Tolero Pharmaceuticals, Inc.
    公开号:EP2970205B1
    公开(公告)日:2019-05-08
查看更多